Lutonix 018 Drug Coated Balloon PTA Catheter
Lutonix · Decision date Jul 9, 2026
What did the FDA approve?
FDA records P170003/S029 as a supplement to PMA P170003, with the supplement type “Real-Time Process”. The recorded decision is approval, dated Jul 9, 2026.
FDA approval order statement
Approval for a change in the paclitaxel (PTx) active pharmaceutical ingredient (API) supplier.
- Regulatory pathway
- PMA supplement
- Supplement type
- Real-Time Process
- Clinical specialty
- Cardiovascular
- Decision date
- Jul 9, 2026
- FDA change category
- Change Design/Components/Specifications/Material
Regulatory record facts
- Identifier
- P170003/S029
- Regulatory pathway
- PMA supplement
- Applicant
- Lutonix
- Product code
- PRC
- Decision code
- APPR
- Decision date
- Jul 9, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Drug-coated peripheral transluminal angioplasty catheter.
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P170003/S028 · Related supplement
Lutonix 018 (Model 9014)
P170003/S029 received
Application receipt date recorded by FDA.
P170003/S029 · FDA decision
Real-Time Process
Timeline entries are records held by MedtechLedger for P170003. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P170003
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Lutonix 018 (Model 9014)P170003/S028 | Lutonix | PMA supplement | Sep 4, 2025 | FDA |
Explore the linked device profile
Other records with product code PRC
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Medtronic Vascular, Inc. | PMA supplement | May 21, 2026 | FDA | |
| Medtronic Vascular, Inc. | PMA supplement | May 1, 2026 | FDA | |
| Medtronic Vascular, Inc. | PMA supplement | Apr 23, 2026 | FDA | |
| Medtronic Vascular, Inc. | PMA supplement | Feb 13, 2026 | FDA | |
| Medtronic Vascular, Inc. | PMA supplement | Jan 30, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Lutonix
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 9409 Science Center Dr., New Hope, MN, 55428
Sources and methodology
- Original FDA record: P170003/S029
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records
